Loading…

Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension

Abstract Objective: To investigate the safety and efficacy of long-term administration of ambrisentan in Japanese adults with pulmonary arterial hypertension (PAH). Research design and methods: In this open-label extension of a preceding multicenter dose-escalation study, 21 Japanese patients with P...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2012-06, Vol.28 (6), p.1069-1076
Main Authors: Yoshida, Shunji, Shirato, Kunio, Shimamura, Ryutaro, Iwase, Takayuki, Aoyagi, Narumi, Nakajima, Hiromu
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective: To investigate the safety and efficacy of long-term administration of ambrisentan in Japanese adults with pulmonary arterial hypertension (PAH). Research design and methods: In this open-label extension of a preceding multicenter dose-escalation study, 21 Japanese patients with PAH received treatment with 5 or 10 mg of ambrisentan once daily and were comprehensively evaluated every 12 weeks. The primary endpoint was the safety of long-term ambrisentan administration, as defined by the incidence and severity of adverse events. The secondary (efficacy) endpoints were change in exercise capacity (as indicated by 6-minute walk distance), World Health Organization functional class, Borg dyspnea index, plasma brain natriuretic peptide level, cardiopulmonary hemodynamics, and time to clinical worsening of PAH. Clinical trial registration: NCT00554619. Results: The mean total duration of treatment (i.e., including the preceding dose-escalation study) was approximately 139 weeks. There were fewer adverse events related to ambrisentan in this study than in the preceding study, and we identified no new safety signals that might preclude the long-term use of ambrisentan among Japanese adults with PAH. Improvements observed in efficacy endpoints in the preceding study were maintained in the present study. Limitations: This study did not include a control group and lacked the statistical power to reach definite conclusions regarding the efficacy of ambrisentan. Conclusion: Our results suggest that long-term administration of ambrisentan is well tolerated and efficacious for Japanese adults with PAH.
ISSN:0300-7995
1473-4877
DOI:10.1185/03007995.2012.685930